A research team led by the School of Public Health in the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with the Center for Immunology & Infection (C2i), has achieved a significant breakthrough in developing broadly protective, live-attenuated influenza vaccines (LAIV).
This article was originally published on MedicalXpress.com